What is the mode of administration for Cordarone (amiodarone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cordarone (Amiodarone) Mode of Administration

Cordarone can be administered both intravenously and orally, with the route selection depending on clinical urgency—IV administration is reserved for life-threatening arrhythmias requiring immediate control, while oral administration is used for chronic maintenance therapy. 1

Intravenous Administration

Initial Dosing for Life-Threatening Arrhythmias

  • Administer 150 mg IV bolus over 10 minutes for ventricular fibrillation or pulseless ventricular tachycardia unresponsive to defibrillation. 2, 3
  • A second 150 mg IV bolus may be given if VF/pulseless VT persists. 3
  • For cardiac arrest scenarios, the American College of Cardiology recommends 300 mg IV bolus when rhythm remains refractory to CPR, defibrillation, and epinephrine. 3

Standard 24-Hour Loading Protocol

  • The recommended first 24-hour dose is approximately 1000 mg delivered as follows: 1
    • Loading infusion: 150 mg over 10 minutes (15 mg/min)
    • Followed by: 360 mg over the next 6 hours (1 mg/min)
    • Maintenance: 540 mg over the remaining 18 hours (0.5 mg/min)
  • After the first 24 hours, continue maintenance infusion at 0.5 mg/min (720 mg per 24 hours). 1
  • Do not exceed an initial infusion rate of 30 mg/min. 1

Critical Administration Requirements

  • Amiodarone must be delivered through a volumetric infusion pump—drop counter infusion sets can result in up to 30% underdosing. 1
  • Administer through a central venous catheter whenever possible, as peripheral vein phlebitis occurs frequently with concentrations > 2 mg/mL. 4, 1
  • Use an in-line filter during administration. 1
  • For infusions longer than 1 hour, do not exceed concentrations of 2 mg/mL unless using a central venous catheter. 1
  • Administer in glass or polyolefin bottles containing D5W for infusions exceeding 2 hours. 1

Contraindications and Monitoring for IV Use

  • IV amiodarone is contraindicated in patients with bradycardia or second/third-degree heart block without a pacemaker. 4, 2
  • IV administration causes bradycardia in 4.9% and hypotension in 16% of patients. 4
  • If bradycardia or heart block develops, discontinue the infusion or reduce the rate immediately. 4
  • Continuous ECG monitoring for heart rate, AV conduction abnormalities, and QT prolongation is mandatory during IV administration. 2

Oral Administration

Loading Dose Strategy

  • The standard oral loading dose is 800-1,600 mg/day in divided doses. 3
  • A common regimen is 600 mg twice daily for 7 days, followed by 600 mg daily thereafter. 5
  • Continue loading until a total of 10 grams has been administered before transitioning to maintenance dosing. 3

Maintenance Dosing

  • The maintenance dose should be 200-400 mg/day after completing the loading phase. 3
  • Clinical experience demonstrates that doses above 600 mg/day are associated with significantly higher rates of side effects (93% of patients). 5
  • Lower maintenance doses (200-300 mg/day) significantly decrease side effects while maintaining efficacy. 6

Transition from IV to Oral

  • When transitioning from IV to oral therapy, clinical monitoring is essential, particularly for elderly patients. 1
  • Monitor closely for breakthrough arrhythmias in the first 6 hours after IV discontinuation. 3
  • The optimal transition dose depends on the duration of IV administration and cumulative dose already given. 1

Important Administration Caveats

Drug Interactions Requiring Dose Adjustments

  • Reduce digoxin dose by 50% when starting amiodarone, as digoxin levels predictably double. 4
  • Monitor prothrombin time/INR at least weekly during the first 6 weeks when co-administered with warfarin, as amiodarone significantly increases anticoagulation effects. 4
  • Amiodarone inhibits CYP 2C9, CYP 2D6, and CYP 3A4 pathways, affecting metabolism of multiple medications including beta-blockers, calcium channel blockers, and narcotics. 4

Dietary Restriction

  • Patients must not consume grapefruit or grapefruit juice during amiodarone therapy, as it inhibits CYP3A-mediated metabolism and increases plasma levels. 4, 1

Special Populations

  • Amiodarone is a Category D drug and is contraindicated in pregnant and breastfeeding women. 6
  • Concomitant use with other AV nodal blocking agents (beta-blockers, calcium channel blockers) creates additive bradycardic effects requiring careful monitoring. 2

References

Guideline

Administering IV Amiodarone with Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Amiodarone Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.

Journal of the American College of Cardiology, 1983

Research

Amiodarone - a 'broad spectrum' antiarrhythmic drug.

Cardiovascular & hematological disorders drug targets, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.